| abstract |
The agent according to the present invention, which comprises, as an active component, any of (1) disulfiram, diethyldithiocarbamate or a metal complex of diethyldithiocarbamate, (2) a pharmaceutically acceptable salt of component (1), and (3) a solvate of component (1) or (2), is to be used for inhibiting interaction between CR2B or CCR5 and front protein, suppressing macrophages, controlling cells constituting cancer microenvironment or inflammatory microenvironment, or potentiating the anticancer activity of an anticancer agent. Moreover, a compound having reduced side effects and improved drug efficacy can be provided by identifying a disulfiram derivative, which has a lower activity of inhibiting aldehyde dehydrogenase and a higher activity of inhibiting front, from among derivatives prepared by modifying the structure of disulfiram. |